[{"id":"29314cf0-3dae-48bb-bacc-9547b377d15c","acronym":"","url":"https://clinicaltrials.gov/study/NCT07471789","created_at":"2026-03-28T01:43:57.744Z","updated_at":"2026-03-28T01:43:57.744Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).","source_id_and_acronym":"NCT07471789","lead_sponsor":"Gyala Therapeutics","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 02/04/2026","start_date":" 02/04/2026","primary_txt":" Primary completion: 05/31/2029","primary_completion_date":" 05/31/2029","study_txt":" Completion: 02/04/2031","study_completion_date":" 02/04/2031","last_update_posted":"2026-03-13"},{"id":"62108e74-4662-481f-afc9-1a0b17537745","acronym":"NCI-2019-04325","url":"https://clinicaltrials.gov/study/NCT04073745","created_at":"2025-03-03T09:56:16.669Z","updated_at":"2025-03-03T09:56:16.669Z","phase":"Phase 1","brief_title":"Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04073745 - NCI-2019-04325","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IL2RA • CD4 • FOXP3 • ISG20","pipe":"","alterations":" ","tags":["IL2RA • CD4 • FOXP3 • ISG20"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 12/04/2019","start_date":" 12/04/2019","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-28"},{"id":"26646272-f3f1-4cb9-84dd-16ded62b0796","acronym":"","url":"https://clinicaltrials.gov/study/NCT01875601","created_at":"2021-01-29T07:04:49.340Z","updated_at":"2025-02-25T12:36:34.409Z","phase":"Phase 1","brief_title":"NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors","source_id_and_acronym":"NCT01875601","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • rhIL-15"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 06/11/2013","start_date":" 06/11/2013","primary_txt":" Primary completion: 09/08/2015","primary_completion_date":" 09/08/2015","study_txt":" Completion: 09/08/2015","study_completion_date":" 09/08/2015","last_update_posted":"2025-02-24"},{"id":"28c966c6-aa0a-48ec-89d0-5286ecccf723","acronym":"","url":"https://clinicaltrials.gov/study/NCT02912559","created_at":"2021-01-18T14:17:52.733Z","updated_at":"2025-02-25T12:26:32.593Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair","source_id_and_acronym":"NCT02912559","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MLH1 • MSH6 • MSH2 • CD4","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MLH1 • MSH6 • MSH2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • 5-fluorouracil • Cotellic (cobimetinib) • oxaliplatin • leucovorin calcium • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 700","initiation":"Initiation: 10/16/2017","start_date":" 10/16/2017","primary_txt":" Primary completion: 04/02/2025","primary_completion_date":" 04/02/2025","study_txt":" Completion: 04/02/2025","study_completion_date":" 04/02/2025","last_update_posted":"2025-02-24"},{"id":"6c31d924-416a-4fac-90f3-4e9e04970c2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04708470","created_at":"2021-01-19T20:51:59.772Z","updated_at":"2025-02-25T12:27:53.092Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers","source_id_and_acronym":"NCT04708470","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jingzhuda (entinostat) • bintrafusp alfa (M7824) • PDS01ADC"],"overall_status":"Recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 10/05/2021","start_date":" 10/05/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-24"},{"id":"7bf4c100-c992-4e7a-9ed8-b32c4d26ea43","acronym":"SWOG 1512","url":"https://clinicaltrials.gov/study/NCT02775851","created_at":"2021-01-18T13:36:44.518Z","updated_at":"2025-02-25T12:26:29.443Z","phase":"Phase 2","brief_title":"Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02775851 - SWOG 1512","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • CD8 • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["TMB • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 02/06/2017","start_date":" 02/06/2017","primary_txt":" Primary completion: 04/14/2023","primary_completion_date":" 04/14/2023","study_txt":" Completion: 05/15/2026","study_completion_date":" 05/15/2026","last_update_posted":"2025-02-24"},{"id":"9d2b54f0-0907-4b8a-b5db-69cd00d54eb2","acronym":"SWOG S1608","url":"https://clinicaltrials.gov/study/NCT03269669","created_at":"2021-01-29T07:15:29.475Z","updated_at":"2025-02-25T12:26:46.064Z","phase":"Phase 2","brief_title":"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","source_id_and_acronym":"NCT03269669 - SWOG S1608","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • doxorubicin hydrochloride • Gazyva (obinutuzumab) • cyclophosphamide • vincristine • prednisone • bendamustine • Ukoniq (umbralisib) • Belrapzo (bendamustine RTD) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 01/23/2018","start_date":" 01/23/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"9e19f934-321f-4e6c-b066-71f0217f0bae","acronym":"","url":"https://clinicaltrials.gov/study/NCT03041688","created_at":"2021-01-18T14:58:33.453Z","updated_at":"2025-02-25T12:26:38.524Z","phase":"Phase 1","brief_title":"Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT03041688","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • CD4","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • TP53 wild-type","tags":["TP53 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • decitabine • navtemadlin (KRT-232)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 02/08/2018","start_date":" 02/08/2018","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-24"},{"id":"a9f39237-1737-4421-910a-0e37d38262b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05083754","created_at":"2023-11-27T22:14:37.322Z","updated_at":"2025-02-25T12:28:25.580Z","phase":"Phase 1","brief_title":"Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma","source_id_and_acronym":"NCT05083754","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PD-L1 • MSI • CD8 • PD-1 • CD4 • ICOS","pipe":"","alterations":" ","tags":["PD-L1 • MSI • CD8 • PD-1 • CD4 • ICOS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • carmustine • Zynyz (retifanlimab-dlwr)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/31/2022","start_date":" 08/31/2022","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-24"},{"id":"bd95cf3a-a05b-4e87-b03d-357c3daa7c72","acronym":"","url":"https://clinicaltrials.gov/study/NCT04628767","created_at":"2021-01-29T07:21:36.268Z","updated_at":"2025-02-25T12:37:42.651Z","phase":"Phase 2/3","brief_title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","source_id_and_acronym":"NCT04628767","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imfinzi (durvalumab) • gemcitabine • doxorubicin hydrochloride • methotrexate • vinblastine • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • Neupogen (filgrastim) • Udenyca (pegfilgrastim-cbqv) • Ziextenzo (pegfilgrastim-bmez) • liposomal gemcitabine (FF-10832) • methotrexate IV"],"overall_status":"Recruiting","enrollment":" Enrollment 249","initiation":"Initiation: 11/12/2021","start_date":" 11/12/2021","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-24"},{"id":"c5926a3c-11fc-4d8b-a13e-2af41702c630","acronym":"","url":"https://clinicaltrials.gov/study/NCT03866382","created_at":"2021-01-18T19:04:09.999Z","updated_at":"2025-02-25T12:37:16.517Z","phase":"Phase 2","brief_title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","source_id_and_acronym":"NCT03866382","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":"","alterations":" ","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 05/13/2019","start_date":" 05/13/2019","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2025-02-24"},{"id":"e26feb64-5ce0-4689-b638-098d6bd0300f","acronym":"E-VIRTUE","url":"https://clinicaltrials.gov/study/NCT06041503","created_at":"2025-02-25T12:29:47.446Z","updated_at":"2025-02-25T12:29:47.446Z","phase":"Phase 2","brief_title":"Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)","source_id_and_acronym":"NCT06041503 - E-VIRTUE","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 02/27/2025","start_date":" 02/27/2025","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2025-02-24"},{"id":"23ac8e6c-a9b5-4a23-995c-206f44787ba3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02890329","created_at":"2021-01-18T14:11:09.765Z","updated_at":"2025-02-25T13:48:17.623Z","phase":"Phase 1","brief_title":"Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia","source_id_and_acronym":"NCT02890329","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" High ALC","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e High ALC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • azacitidine • decitabine • CS1002 (ipilimumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 09/05/2017","start_date":" 09/05/2017","primary_txt":" Primary completion: 10/24/2022","primary_completion_date":" 10/24/2022","study_txt":" Completion: 08/19/2025","study_completion_date":" 08/19/2025","last_update_posted":"2025-02-21"},{"id":"4cfc5715-dc42-47d6-8b29-f4162141b070","acronym":"20-C-0012","url":"https://clinicaltrials.gov/study/NCT04235777","created_at":"2021-01-29T07:20:15.829Z","updated_at":"2025-02-25T13:40:02.108Z","phase":"Phase 1","brief_title":"Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies","source_id_and_acronym":"NCT04235777 - 20-C-0012","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • PDS01ADC"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-21"},{"id":"913a7f90-f43b-43fc-9a5c-45399bce2739","acronym":"","url":"https://clinicaltrials.gov/study/NCT03907475","created_at":"2021-01-18T19:14:04.518Z","updated_at":"2025-02-25T13:39:50.577Z","phase":"Phase 2","brief_title":"Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study)","source_id_and_acronym":"NCT03907475","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • CD4 • IL2","pipe":"","alterations":" ","tags":["TMB • CD4 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • gemcitabine • capecitabine • albumin-bound paclitaxel • pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 07/16/2019","start_date":" 07/16/2019","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-21"},{"id":"a8eb30bd-0fe3-47c6-8e1f-dbc91b74bace","acronym":"ARCITECT","url":"https://clinicaltrials.gov/study/NCT05928806","created_at":"2023-07-03T16:10:37.286Z","updated_at":"2025-02-25T13:41:35.328Z","phase":"Phase 2","brief_title":"Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial","source_id_and_acronym":"NCT05928806 - ARCITECT","lead_sponsor":"Michael B. Atkins, MD","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/25/2023","start_date":" 09/25/2023","primary_txt":" Primary completion: 10/10/2025","primary_completion_date":" 10/10/2025","study_txt":" Completion: 10/12/2026","study_completion_date":" 10/12/2026","last_update_posted":"2025-02-21"},{"id":"5b783b7c-5a42-40ed-b63a-61150837a02a","acronym":"A021804","url":"https://clinicaltrials.gov/study/NCT04394858","created_at":"2021-01-29T07:20:43.079Z","updated_at":"2025-02-25T13:53:17.999Z","phase":"Phase 2","brief_title":"Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer","source_id_and_acronym":"NCT04394858 - A021804","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MGMT • CD4","pipe":"","alterations":" ","tags":["MGMT • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 03/17/2021","start_date":" 03/17/2021","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2025-02-20"},{"id":"b94d3fe3-9040-4df9-8c37-231f34f9f98f","acronym":"POLESTAR","url":"https://clinicaltrials.gov/study/NCT05268510","created_at":"2022-03-07T18:53:55.391Z","updated_at":"2025-02-25T13:54:16.446Z","phase":"Phase 2","brief_title":"Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma","source_id_and_acronym":"NCT05268510 - POLESTAR","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" HER-2 • PD-L1 • CD8 • CD4","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1 • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib) • capecitabine • oxaliplatin"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 09/15/2022","start_date":" 09/15/2022","primary_txt":" Primary completion: 08/27/2024","primary_completion_date":" 08/27/2024","study_txt":" Completion: 01/09/2025","study_completion_date":" 01/09/2025","last_update_posted":"2025-02-20"},{"id":"da3b2b09-ed01-4312-97c2-dda82f0fd6ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT04799275","created_at":"2021-03-16T18:52:53.431Z","updated_at":"2025-02-25T13:53:42.140Z","phase":"Phase 2/3","brief_title":"Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT04799275","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • BCL6 • CD4","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Onureg (azacitidine oral) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 422","initiation":"Initiation: 05/20/2021","start_date":" 05/20/2021","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2025-02-20"},{"id":"e2ff7fb5-f1de-4b7f-9fd4-438675875b61","acronym":"","url":"https://clinicaltrials.gov/study/NCT02160015","created_at":"2021-01-18T10:03:19.018Z","updated_at":"2025-02-25T13:52:04.076Z","phase":"Phase 1","brief_title":"Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02160015","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD4 • CD5 • FCER2","pipe":"","alterations":" ","tags":["CD20 • CD4 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 05/20/2014","start_date":" 05/20/2014","primary_txt":" Primary completion: 03/27/2017","primary_completion_date":" 03/27/2017","study_txt":" Completion: 08/13/2025","study_completion_date":" 08/13/2025","last_update_posted":"2025-02-20"},{"id":"f99d43e2-a88e-46e7-9ba6-67aaeb1cdec6","acronym":"RTOG 1216","url":"https://clinicaltrials.gov/study/NCT01810913","created_at":"2021-01-18T08:01:55.190Z","updated_at":"2025-02-25T13:52:01.448Z","phase":"Phase 2/3","brief_title":"Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer","source_id_and_acronym":"NCT01810913 - RTOG 1216","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • CD4","pipe":" | ","alterations":" CDKN2A negative","tags":["EGFR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • docetaxel • Datalai (cetuximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 613","initiation":"Initiation: 03/22/2013","start_date":" 03/22/2013","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-20"},{"id":"087d5cdf-3bbf-47a4-a244-528df8b9dbc9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06833866","created_at":"2025-02-25T14:13:40.666Z","updated_at":"2025-02-25T14:13:40.666Z","phase":"Phase 1","brief_title":"Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06833866","lead_sponsor":"The Methodist Hospital Research Institute","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • irinotecan"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 12/04/2024","start_date":" 12/04/2024","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-19"},{"id":"1bb11f50-7b59-4eb4-901f-d7b6ac9b157d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04287868","created_at":"2021-01-18T20:48:45.296Z","updated_at":"2025-02-25T14:07:41.725Z","phase":"Phase 1/2","brief_title":"Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies","source_id_and_acronym":"NCT04287868","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CDKN2A • CD4","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1 • CDKN2A • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • Versamune HPV • PDS01ADC"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 06/09/2020","start_date":" 06/09/2020","primary_txt":" Primary completion: 07/26/2022","primary_completion_date":" 07/26/2022","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-19"},{"id":"5325032a-dfb5-4381-8e59-f5e1418ec3ae","acronym":"DASH","url":"https://clinicaltrials.gov/study/NCT04704661","created_at":"2021-01-19T20:51:17.334Z","updated_at":"2025-02-25T14:02:10.901Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","source_id_and_acronym":"NCT04704661 - DASH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TP53 • ATM • RAS • CD4","pipe":" | ","alterations":" HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation","tags":["HER-2 • TP53 • ATM • RAS • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 08/09/2021","start_date":" 08/09/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-19"}]